Seeking Alpha
 

Acura Pharmaceuticals, Inc. (ACUR)

- NASDAQ
  • Thu, May 21, 10:58 AM
    • Thinly traded nano cap Intellipharmaceutics (IPCI +17.3%) heads north on a 10x surge in volume in response to its announcement that the FDA may not require a Phase 3 study for its abuse-deterrent opioid candidate, Rexista Oxycodone XR, if bioequivalence to Purdue Pharma's Oxycontin is demonstrated. The company believes that its previously completed Phase 1 trials fulfill this criterion.
    • The firm intends to file its New Drug Application (NDA) within the next 6 - 12 months. Approval is not guaranteed, however. After reviewing the data, the FDA may still require further studies.
    • Rexista Oxycodone XR's formulation deters abuse by instantaneously coagulating and entrapping the drug in a viscous hydrogel when pulverized and hydrated. It is also designed to prevent dose dumping if taken with alcohol.
    • Related tickers: (PTIE -1.9%)(DRRX)(COLL +1.9%)(ZGNX)(MNK -0.3%)(ACT +1.1%)(TEVA +1.6%)(ABBV -0.7%)(LCI -0.7%)(ALKS -1%)(EGLT -0.1%)(PFE -0.2%)(ACUR -2.4%)
    | 12 Comments
  • Mon, May 4, 4:27 PM
    • Acura Pharmaceuticals (NASDAQ:ACUR): Q1 EPS of $0.03 beats by $0.04.
    • Revenue of $5.4M misses by $2.2M.
    • Press Release
    | 1 Comment
  • Wed, Mar. 25, 11:47 AM
    • A study in 12 healthy subjects shows that Acura Pharmaceuticals' (ACUR +2.9%) Nexafed (pseudoephedrine HCl) is bioequivalent to J&J's Sudafed (pseudoephedrine HCl) 12-Hour Tablets, which is the company's first foray into an extended-release formulation with its IMPEDE 2.0 methamphetamine-resistant technology. It intends to request a pre-IND meeting with the FDA to review the data and discuss a complete development program.
    • IMPEDE is a polymer matrix that disrupts the conversion of pseudoephedrine into methamphetamine by forming a thick gel when dissolved in solvents used in the methamphetamine production process. The company launched Nexafed 30 mg tablets in December 2012 and Nexafed Sinus Pressure + Pain 30/325 mg tablets in February 2015, both of which utilize IMPEDE.
    | Comment!
  • Wed, Mar. 11, 10:01 AM
    • Based on feedback from the FDA, Egalet (EGLT) now plans to submit a New Drug Application (NDA) for its abuse-deterrent, extended-release oral morphine product, Egalet-001, by the end of the year.
    • The company will initiate a pivotal bioequivalence study comparing the 60 mg dose to Purdue's MS Contin later this month. Bioequivalence to MS Contin has already been demonstrated at the 15 mg and 30 mg doses.
    • Egalet-001 incorporates the company's Guardian Technology to deter abuse. It utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew or dissolve. It also turns to gel when exposed to water.
    • Related tickers: (ZGNX -23.4%)(ACUR)(ALKS +0.5%)(PFE +0.6%)(ABBV +0.7%)(LCI +1.6%)(ACT +1.7%)(MNK +1.6%)(TEVA +2.6%)
    | 3 Comments
  • Tue, Mar. 10, 8:01 AM
    • Privately-held Collegium Pharmaceutical raises $50M from institutional investors to fund the advancement of its abuse-deterrent product candidate, Xtampa ER (oxycodone extended-release capsules) through FDA clearance and commercial launch as well as fund operational growth and other pipeline programs.
    • The FDA accepted the company's New Drug Application (NDA) for Xtampa ER in February. Its abuse-deterrent technology is called DETERx, which combines oxycodone with fatty acid and waxes to form small spherical beads which resist particle size reduction and dose dumping when subjected to breaking, crushing, chewing and dissolving.
    • Previously: FDA accepts Collegium's NDA for abuse-deterrent opioid (Feb. 17)
    • Related tickers: (NASDAQ:ZGNX) (NYSE:MNK) (NYSE:ACT) (NYSE:TEVA) (NYSE:ABBV) (NYSE:LCI) (NASDAQ:ALKS) (NASDAQ:EGLT) (NYSE:PFE) (NASDAQ:ACUR)
    | Comment!
  • Tue, Mar. 3, 10:54 AM
    • Acura Pharmaceuticals (ACUR -7.5%) Q4 results: Revenues: $0.5M (+999%); COGS: $0.04M (+8.3%); R&D Expense: $0.9M (+12.5%); SG&A: $2M (-28.6%); Operating Loss: ($2.5M) (+28.6%); Net Loss: ($2.7M) (+20.6%); Loss Per Share: ($0.06) (+14.3%).
    • FY2014 results: Revenues: $0.8M (+700.0%); COGS: $0.2M (+100.0%); R&D Expense: $4.6M (-6.1%); SG&A: $7.9M (-11.2%); Operating Loss: ($12.2M) (+13.5%); Net Loss: ($13.2M) (+5.0%); Loss Per Share: ($0.27) (+6.9%); Quick Assets: $12.1M.
    • No guidance given.
    | 1 Comment
  • Mon, Mar. 2, 4:25 PM
    • Acura Pharmaceuticals (NASDAQ:ACUR): Q4 EPS of -$0.06 beats by $0.03.
    • Revenue of $0.53M (+1225.0% Y/Y) beats by $0.48M.
    • Press Release
    | Comment!
  • Wed, Feb. 25, 9:42 AM
    • The FDA accepts for review the New Drug Application (NDA) from Teva Pharmaceutical Industries (TEVA -0.6%) for CEP-33237, its hydrocodone bitartrate extended release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
    • The product is formulated with its proprietary abuse-deterrent technology, although it does not specify the nature of the technology or how it works. In an oral human abuse liability study (HAL) in nondependent recreational opioid users, the abuse potential of finely crushed CEP-33237 powder was significantly lower based on peak at-the-moment drug liking. An intranasal HAL study produced the same result.
    • Related tickers: (ZGNX -0.6%)(EGLT)(OTCQB:ELTP)(PFE -0.7%)(ACUR)(MNK -0.6%)(ACT +0.7%)(ABBV -0.6%)(LCI +1%)(ALKS -1.7%)
    | 3 Comments
  • Tue, Feb. 17, 10:06 PM
    • Elite Pharmaceuticals (OTCQB:ELTP) plans to commence a Phase 3 study in late March evaluating its abuse-deterrent opioid product candidate, ELI-200. The company has submitted a study protocol to the FDA and expects to receive its comments by mid-March. Patient dosing should start shortly thereafter.
    • The multi-center, randomized, double-blind, placebo-controlled, parallel group clinical trial will assess the safety and efficacy of abuse-deterrent ELI-200 for the treatment of adult patients with moderate-to-severe pain following surgery. The study will enroll ~150 patients and will take ~eight weeks to complete.
    • Elite projects submitting a New Drug Application (NDA) in Q3 and achieving regulatory clearance by early 2016.
    • The company's abuse-deterrent technology is a multi-particulate capsule that contains an opioid agonist in addition to the opioid antagonist, naltrexone. If the multi-particulate beads are crushed or dissolved, the naltrexone is released which blocks the effects of the opioid. The technology is the firm's top priority, expected to add considerably to its modest revenues to date. Fiscal Q3's top line was only $1.4M.
    • Related tickers: (NYSE:PFE) (NASDAQ:ACUR) (NASDAQ:ZGNX) (NYSE:MNK) (NYSE:ACT) (NYSE:TEVA) (NYSE:ABBV) (NYSE:LCI) (NASDAQ:ALKS) (NASDAQ:EGLT)
    | 67 Comments
  • Tue, Feb. 17, 8:40 AM
    • The FDA accepts for review the New Drug Application (NDA) from privately-held Canton, MA-based Collegium Pharmaceuticals for Xtampza ER, its abuse-deterrent extended-release oxycodone formulation for the treatment of chronic pain.
    • Its abuse-deterrent technology is called DETERx, which preserves the extended-release properties following common methods of tampering. It also avoids the use of antagonists (Pfizer's (NYSE:PFE) ALO-02 and Embeda) and aversive agents (Acura's (NASDAQ:ACUR) AVERSION), thereby minimizing the risks to legitimate patients.
    • Related tickers: (NASDAQ:ZGNX) (NYSE:MNK) (NYSE:ACT) (NYSE:TEVA) (NYSE:ABBV) (NYSE:LCI) (NASDAQ:ALKS) (NASDAQ:EGLT)
    | 1 Comment
  • Fri, Jan. 23, 11:38 AM
    • Thinly-traded nano cap Egalet (EGLT +32.7%) has jumped almost 60% since yesterday in response to its announcement of positive results from a Category 3 human abuse liability (HAL) study of Egalet-001 (abuse deterrent extended release oral morphine). The study showed that the abuse potential of Egalet-101 taken orally was significantly lower than that for manipulated MS Contin (morphine sulfate controlled-release).
    • Egalet-001's abuse deterrent characteristics are based on the company's Guardian technology which makes the pill extremely hard, difficult to chew and resists common methods of physical and chemical manipulation. For example, it turns to gel when exposed to water.
    • The company will disclose the results from additional abuse-deterrent studies later this year.
    • Related tickers: (ZGNX +2.3%)(ACUR -1.6%)(ALKS +0.4%)
    | Comment!
  • Thu, Jan. 8, 9:17 AM
    • Acura Pharmaceuticals (NASDAQ:ACUR) enters into a Collaboration and License Agreement with subsidiaries of Egalet Ltd. (NASDAQ:EGLT) for the worldwide commercialization Acura's immediate release oxycodone hydrochloride tablets which incorporates its Aversion abuse-deterrent platform.
    • Egalet will market the product under the brand name Oxaydo. It is currently FDA-approved in 5 mg and 7.5 mg strengths for the treatment of acute and chronic moderate-to-severe pain.
    • The company will host a conference call tomorrow at 8:30 am ET to discuss the agreement.
    | Comment!
  • Dec. 25, 2014, 12:41 PM
    • Endo International plc (NASDAQ:ENDP) subsidiary Endo Pharmaceuticals and BioDelivery Sciences (NASDAQ:BDSI) submit a New Drug Application (NDA) to the FDA for Buprenorphine HCl Buccal Film for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
    • The product uses BioDelivery's BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine across the buccal mucosa (inside lining of the cheek) via a thin film that adheres to the cheek lining in less than five seconds and then completely dissolves.
    • Buprenorphine is a partial mu-opioid receptor agonist and a kappa antagonist which is different than full mu-opioid agonists like morphine. It is a Schedule III controlled substance which has a lower abuse potential than Schedule II drugs.
    • Opioid-related tickers: (NASDAQ:ZGNX) (NYSE:PFE) (NASDAQ:EGLT) (NASDAQ:ACUR) (NYSE:MNK) (NYSE:ABBV) (NYSE:TEVA) (NASDAQ:ALKS)
    | Comment!
  • Nov. 20, 2014, 1:36 PM
    • The FDA approves Purdue Pharma's Hysingla ER (hydrocodone bitartrate) for pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
    • Hysingla ER incorporates abuse-deterrent properties that make the tablet difficult to crush, break or dissolve and it forms a viscous hydrogel that makes it difficult to prepare for injection.
    • The agency is requiring postmarketing studies of Hysingla ER to assess the effects of its abuse-deterrent properties on the risk of abuse and the consequences of that abuse in the community. Purdue is also required to make educational programs available to healthcare professionals on now to safely prescribe ER/LA opioid analgesics in addition to medication guides and patient counseling documents.
    • Opioid-related tickers: (ZGNX -0.8%)(PFE +0.2%)(EGLT +4.5%)(ACUR)(MNK +0.9%)(ABBV)(TEVA -0.1%)(ALKS +1.5%)
    | 1 Comment
  • Nov. 3, 2014, 4:33 PM
    • Acura Pharmaceuticals (NASDAQ:ACUR): Q3 EPS of -$0.06 beats by $0.02.
    • Revenue of $0.15M (+87.5% Y/Y) beats by $0.07M.
    • Press Release
    | Comment!
  • Oct. 28, 2014, 12:03 PM
    • Acura Pharmaceuticals (ACUR) will report Q3 results on November 3 after the close. The conference call will begin the next day, November 4, at 7:30 am CT/8:30 am ET.
    • Consensus view is a loss of ($0.08) on revenues of $80K.
    | Comment!
Visit Seeking Alpha's
ACUR vs. ETF Alternatives
Company Description
Acura Pharmaceuticals Inc is a pharmaceutical company. It is engaged in the research, development & manufacture of productto address medication abuse & misuse, utilizing the Company's proprietary, tamper-resistant AVERSION& IMPEDEtechnology platforms.